Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSV-allo for COVID-19 Pneumonia
NCT04361942Phase 2Completed
- Sponsor
- Red de Terapia Celular
- Start
- May 2020
- Primary completion
- Oct 2021
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing MSV-allo with Placebo (2 arms). Primary endpoints: Proportion of patients in whom removal of invasive mechanical ventilation (IMV) has been achieved and Overall survival. Started May 2020; status: completed.
02
Drugs
MSV-allo
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04361942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361942.